AZD0901 compared with Investigator’s choice of therapy in participants with second- or later-line advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing Claudin18.2

Study identifier:D9802C00001

ClinicalTrials.gov identifier:NCT06346392

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Medical condition

gastric cancer

Phase

Phase 3

Healthy volunteers

No

Study drug

AZD0901, Ramucirumab+ paclitaxel, Paclitaxel, Docetaxel, Irinotecan, TAS-102, Apatinib

Sex

All

Estimated Enrollment

589

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 04 Mar 2024
Estimated Primary Completion Date: 10 Apr 2026
Estimated Study Completion Date: 09 Oct 2026

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria